Efficacy and effectiveness of anti-HBV therapy with early withdrawal of HBIG prophylaxis to prevent HBV recurrence following liver transplantation

Bibliography

• Hepatitis B Foundation. Available from: http://www.hepb.org/hepb/statistics.htm [Cited 17 June 2014]
   Google Scholar
• Organ Procurement and Transplantation Network (OPTN). 2013. Available from: http://optn.transplant.hrsa.gov/converge/data/ [ Cited 05 September 2014]
   Google Scholar
• Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004;10(10 Suppl 2):S74-85
   PubMed Web of Science ®Google Scholar
• Fox AN, Terrault NA. The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol 2012;56(5):1189-97
   PubMed Web of Science ®Google Scholar
• Lok AS. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002;8(10 Suppl 1):S67-73
   PubMed Web of Science ®Google Scholar
• Dindoost P, Jazayeri SM, Alavian SM. Hepatitis B immune globulin in liver transplantation prophylaxis: an update. Hepat Mon 2012;12(3):168-76
   Web of Science ®Google Scholar
• User Fee BIllable Biologic Products and Potentices approved under Section 351 of the PHS Act. 2014. Available from: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm122936.htm [ Cited 07 September 2014]
   Google Scholar
• Hepagam B® Prescribing Information. 2012. Available from: http://www.hepagamb.com/pdf/HepaGamBPI.pdf [ Cited 07 September 2014]
   Google Scholar
• Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology (Baltimore, Md) 2014;59(2):434-42
   PubMed Web of Science ®Google Scholar
• Lok AS. Entecavir in the treatment of Chronic Hepatitis B. 2014. Available from: http://www.uptodate.com/contents/entecavir-in-the-treatment-of-chronic-hepatitis-b-virus-infection [ Cited 17 June 2014]
   Google Scholar
• Marcellin P, Gane E, Tsai N, et al. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance [AASLD Abstract 926]. Hepatology (Baltimore, Md) 2013;58(S1):649A
   Google Scholar
• Saab S, Desai S, Tsaoi D, et al. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011;11(3):511-17
   PubMed Web of Science ®Google Scholar
• Terrault N. Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era? Am J Gastroenterol 2013;108(6):949-51
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from: http://www.cochrane-handbook.org [Cited 13 September 2014]
   Google Scholar
• Tanaka T, Benmousa A, Marquez M, et al. The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. Clin Transplant 2012;26(5):E561-9
   PubMed Web of Science ®Google Scholar
• Tanaka T, Renner EL, Selzner N, et al. One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. Can J Gastroenterol Hepatol 2014;28(1):41-4
   PubMed Web of Science ®Google Scholar
• Yi NJ, Choi JY, Suh KS, et al. Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. J Gastroenterol 2013;48(12):1401-10
   PubMed Web of Science ®Google Scholar
• Angus PW, Patterson SJ, Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology (Baltimore, Md) 2008;48(5):1460-6
   PubMed Web of Science ®Google Scholar
• Teperman LW, Poordad F, Bzowej N, et al. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transplant 2013;19(6):594-601
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Goulis I, Antoniadis N, et al. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transplant Int 2014;27(10):1022-8
   PubMed Web of Science ®Google Scholar
• Ahn J, Cohen SM. Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin. Hepat Mon 2011;11(8):638-45
   Web of Science ®Google Scholar
• Neff GW, Kemmer N, Kaiser TE, et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007;52(10):2497-500
   PubMed Web of Science ®Google Scholar
• Gane EJ, Patterson S, Strasser SI, et al. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl 2013;19(3):268-74
   PubMed Web of Science ®Google Scholar
• Nath DS, Kalis A, Nelson S, et al. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006;20(2):206-10
   PubMed Web of Science ®Google Scholar
• Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003;38(6):811-17
   PubMed Web of Science ®Google Scholar
• Buti M, Mas A, Prieto M, et al. Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007;84(5):650-4
   PubMed Web of Science ®Google Scholar
• Park SJ, Paik SW, Choi MS, et al. Is lamivudine with 1-week HBlg as effective as long-term high-dose HBlg in HBV prophylaxis after liver transplantation? Transplant Proc 2002;34(4):1252-4
   PubMed Web of Science ®Google Scholar
• Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011;141(4):1212-19
   PubMed Web of Science ®Google Scholar
• Fung J, Chan SC, Cheung C, et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol 2013;108(6):942-8
   PubMed Web of Science ®Google Scholar
• Wadhawan M, Gupta S, Goyal N, et al. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis. Liver Transplant 2013;19(9):1030-5
   PubMed Web of Science ®Google Scholar
• Takaki A, Yagi T, Iwasaki Y, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007;83(2):231-3
   PubMed Web of Science ®Google Scholar
• Kawagishi N, Takeda I, Miyagi S, et al. Nucleoside analogue therapy following one-year course of hepatitis B immunoglobulin in preventing hepatitis B virus reactivation after living donor liver transplantation. Tohoku J Exp Med 2010;222(4):275-9
   PubMed Web of Science ®Google Scholar